Answers are grounded in this paper and cite their sources.
Mutations in TP53 are common in non-small cell lung cancer. Apart from the loss of tumor-suppressor functions, TP53 mutations may result in gain of function favoring cellular proliferation, inhibition of apoptosis, and genomic instability. Some TP53 mutations are more likely to affect the course of the disease than others.
No takes yet. Share an insight, caveat, or question.
Govindan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: